PMID- 29278655
OWN - NLM
STAT- MEDLINE
DCOM- 20180810
LR  - 20180810
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 33
IP  - 5
DP  - 2018 May
TI  - Eosinophilic esophagitis in Japan: Focus on response to acid suppressive therapy.
PG  - 1016-1022
LID - 10.1111/jgh.14079 [doi]
AB  - Eosinophilic esophagitis (EoE) is a chronic inflammatory condition characterized 
      by esophageal dysfunction and dense eosinophilic infiltration of esophageal 
      epithelium. According to clinical consensus and guidelines published in 2011, 
      esophageal eosinophilia was classified into two entities based on response to 
      proton pump inhibitor (PPI) administration: EoE and PPI-responsive esophageal 
      eosinophilia (PPI-REE). We have performed a series of investigations to determine 
      whether EoE is actually different from PPI-REE. Consistent with Western reports, 
      more than half of our examined patients with symptomatic esophageal eosinophilia 
      suggestive of EoE achieved histological remission with single PPI therapy. 
      Furthermore, our comparisons of clinical, endoscopic, and histopathological 
      findings between patients with EoE and those with PPI-REE revealed nearly no 
      differences between them. We also compared gene expression profiles in mucosal 
      biopsy specimens between those groups and found that microarray findings obtained 
      from PPI-REE patients substantially overlapped with those from EoE patients, 
      suggesting that both represent the same condition or are variations of a single 
      disease. In addition, we have noted that more than half of EoE patients who show 
      resistance to a PPI therapy respond to vonoprazan, a novel potassium-competitive 
      acid blocker that has been shown to provide more potent and sustained suppression 
      of gastric acid secretion than PPIs. Our results indicate that PPI-REE may 
      constitute a subtype of EoE. Based on novel evidence including results obtained 
      in our studies, the most recently updated guidelines have included responders to 
      PPI therapy within the spectrum of EoE, abandoning the term PPI-REE.
CI  - (c) 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & 
      Sons Australia, Ltd.
FAU - Ishimura, Norihisa
AU  - Ishimura N
AD  - Department of Gastroenterology and Hepatology, Shimane University School of 
      Medicine, Izumo, Japan.
FAU - Kinoshita, Yoshikazu
AU  - Kinoshita Y
AD  - Department of Gastroenterology and Hepatology, Shimane University School of 
      Medicine, Izumo, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180309
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 
      (1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Pyrroles)
RN  - 0 (Sulfonamides)
SB  - IM
MH  - Adult
MH  - Chronic Disease
MH  - Eosinophilic Esophagitis/classification/*drug therapy/epidemiology/etiology
MH  - Female
MH  - Humans
MH  - Japan/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Proton Pump Inhibitors/*administration & dosage
MH  - Pyrroles/administration & dosage
MH  - Sulfonamides/administration & dosage
OTO - NOTNLM
OT  - eosinophilic esophagitis
OT  - esophageal eosinophilia
OT  - proton pump inhibitor
EDAT- 2017/12/27 06:00
MHDA- 2018/08/11 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/04 00:00 [received]
PHST- 2017/12/14 00:00 [revised]
PHST- 2017/12/19 00:00 [accepted]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/08/11 06:00 [medline]
PHST- 2017/12/27 06:00 [entrez]
AID - 10.1111/jgh.14079 [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2018 May;33(5):1016-1022. doi: 10.1111/jgh.14079. Epub 
      2018 Mar 9.